iTeos Therapeutics, Inc. (ITOS)
| Market Cap | 633.11M |
| Revenue (ttm) | 497.30M |
| Net Income (ttm) | 297.64M |
| Shares Out | 36.62M |
| EPS (ttm) | 7.72 |
| PE Ratio | 2.24 |
| Forward PE | 9.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96,995 |
| Open | 16.79 |
| Previous Close | 16.84 |
| Day's Range | 16.25 - 17.49 |
| 52-Week Range | 16.21 - 52.43 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 52.43 (+203.2%) |
| Earnings Date | May 12, 2022 |
About ITOS
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote a...
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for ITOS stock is "Buy." The 12-month stock price forecast is 52.43, which is an increase of 203.24% from the latest price.
News
ITeos Therapeutics, Inc. (ITOS) Surpasses Q1 Earnings and Revenue Estimates
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 127.50% and 140.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
iTeos Reports First Quarter 2022 Financial Results and Provides Business Update
WATERTOWN, Mass. and GOSSELIES, Belgium, May 12, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...
Innoskel Appoints Dr Michel Detheux as Chairman
Inno s kel Appoints Dr Michel Detheux as Chairman
iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022
WATERTOWN, Mass. and GOSSELIES, Belgium, April 08, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development o...
ITeos Therapeutics, Inc. (ITOS) Tops Q4 Earnings and Revenue Estimates
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 278.29% and 181.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s...
iTeos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
- Entered into landmark collaboration with GSK for EOS-448/GSK4428859A; began dosing patients in Jemperli (dostarlimab -gxly) and EOS-448 combination trial and announced plans to initiate multiple regis...
iTeos to Present at the Cowen 42nd Annual Health Care Conference
CAMBRIDGE, Mass. and GOSSELIES, Belgium, March 01, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development o...
5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates
Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.
iTeos to Participate in Upcoming Investor Conferences in February
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 10, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...
iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 10, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...
Why iTeos Therapeutics Topped the Market Today
The stock is about to become a component of a high-profile index.
iTeos to Present at the 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...
iTeos Therapeutics Set to Join S&P SmallCap 600
NEW YORK, Dec. 31, 2021 /PRNewswire/ -- iTeos Therapeutics Inc. (NASD: ITOS) will replace Magellan Health Inc. (NASD: MGLN) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday...
iTeos Announces New Data for its Anti-TIGIT Antibody, EOS-448, at the American Society of Hematology Annual Meeting a...
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Dec. 09, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...
MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to its Investment Committee
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Detlev Biniszkiewicz, Ph.D. added to MPM Investment Committee
Why iTeos Therapeutics, Inc. (ITOS) Might be Well Poised for a Surge
iTeos Therapeutics, Inc. (ITOS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 53%: Here's is How to Trade
The consensus price target hints at a 53.3% upside potential for iTeos Therapeutics, Inc. (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear...
ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -62.42% and -68.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the ...
iTeos Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
- First patients dosed in clinical trial of anti-TIGIT monoclonal antibody, EOS-448, in combination with pembrolizumab and with inupadenant in patients with solid tumors
iTeos to Report Third Quarter 2021 Financial Results on November 10, 2021
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...
iTeos Reports Second Quarter 2021 Financial Results and Provides Business Update
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 12, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...
iTeos Therapeutics to Present at Wedbush PacGrow Healthcare Conference 2021
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...
iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021
CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 08, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of...
Glaxo (GSK)/iTeos Therapeutics to Co-Develop Novel Cancer Drug
Glaxo (GSK) signs deal with iTeos Therapeutics to co-develop its investigational cancer candidate known as EOS-448. Glaxo will also study EOS-448 with its other investigational cancer therapies.